Zambelli, Alberto
 Distribuzione geografica
Continente #
AS - Asia 3.318
NA - Nord America 2.866
EU - Europa 1.001
SA - Sud America 940
AF - Africa 205
OC - Oceania 21
Continente sconosciuto - Info sul continente non disponibili 6
Totale 8.357
Nazione #
US - Stati Uniti d'America 2.760
SG - Singapore 1.847
BR - Brasile 734
CN - Cina 650
VN - Vietnam 404
FI - Finlandia 189
NG - Nigeria 145
IE - Irlanda 134
DE - Germania 124
IT - Italia 108
GB - Regno Unito 97
FR - Francia 96
HK - Hong Kong 94
AR - Argentina 88
IN - India 70
NL - Olanda 48
ID - Indonesia 43
RU - Federazione Russa 40
MX - Messico 38
CA - Canada 36
EC - Ecuador 35
IQ - Iraq 30
BD - Bangladesh 28
SE - Svezia 28
PL - Polonia 23
CL - Cile 20
JP - Giappone 20
ZA - Sudafrica 20
AU - Australia 19
ES - Italia 19
UA - Ucraina 19
CO - Colombia 18
PK - Pakistan 17
PY - Paraguay 17
MA - Marocco 14
UZ - Uzbekistan 12
VE - Venezuela 12
TR - Turchia 11
KZ - Kazakistan 10
CZ - Repubblica Ceca 9
IL - Israele 9
LT - Lituania 8
EG - Egitto 7
NO - Norvegia 7
PA - Panama 7
SA - Arabia Saudita 7
BE - Belgio 6
DO - Repubblica Dominicana 6
KE - Kenya 6
OM - Oman 6
RO - Romania 6
A2 - ???statistics.table.value.countryCode.A2??? 5
AT - Austria 5
BG - Bulgaria 5
BH - Bahrain 5
BO - Bolivia 5
CR - Costa Rica 5
JO - Giordania 5
PE - Perù 5
PH - Filippine 5
TH - Thailandia 5
AE - Emirati Arabi Uniti 4
AZ - Azerbaigian 4
CH - Svizzera 4
PT - Portogallo 4
TN - Tunisia 4
TW - Taiwan 4
UY - Uruguay 4
AL - Albania 3
DK - Danimarca 3
DZ - Algeria 3
GR - Grecia 3
GT - Guatemala 3
IR - Iran 3
JM - Giamaica 3
KG - Kirghizistan 3
MY - Malesia 3
NP - Nepal 3
SV - El Salvador 3
AM - Armenia 2
BY - Bielorussia 2
CY - Cipro 2
EE - Estonia 2
ET - Etiopia 2
GE - Georgia 2
HN - Honduras 2
HR - Croazia 2
KR - Corea 2
MD - Moldavia 2
SY - Repubblica araba siriana 2
TT - Trinidad e Tobago 2
AO - Angola 1
BN - Brunei Darussalam 1
CI - Costa d'Avorio 1
EU - Europa 1
GY - Guiana 1
HU - Ungheria 1
KI - Kiribati 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
Totale 8.345
Città #
Singapore 781
Ashburn 355
The Dalles 313
Shanghai 239
Chandler 218
San Jose 203
New York 194
Helsinki 189
Beijing 158
Ho Chi Minh City 157
Benin City 143
Dublin 133
Princeton 114
Lawrence 113
Dallas 112
Hanoi 88
Hong Kong 84
Wilmington 76
Boardman 63
São Paulo 61
Paris 59
Los Angeles 55
London 43
Amsterdam 36
Rio de Janeiro 29
San Mateo 29
Phoenix 22
Santa Clara 22
Warsaw 19
Brasília 18
Milan 18
Ann Arbor 16
Belo Horizonte 16
Brooklyn 15
Da Nang 15
Fairfield 15
Haiphong 15
Chennai 14
Montreal 14
Guayaquil 13
Leawood 13
Mumbai 13
Johannesburg 12
Salvador 12
Seattle 12
Tokyo 12
Boston 11
Quito 11
Tashkent 11
Thái Bình 11
Buenos Aires 10
Falkenstein 10
Fortaleza 10
Frankfurt am Main 10
Mexico City 10
Porto Alegre 10
Asunción 9
Baghdad 9
Curitiba 9
Munich 9
Orem 9
Poplar 9
Assago 8
Biên Hòa 8
Florence 8
Thái Nguyên 8
Woodbridge 8
Cincinnati 7
Denver 7
Hải Dương 7
Kyiv 7
Moscow 7
Naples 7
Pune 7
Reston 7
Ribeirão Preto 7
San Francisco 7
Santo André 7
Stockholm 7
Belém 6
Brno 6
Brussels 6
Cairo 6
Council Bluffs 6
Erbil 6
Evanston 6
Guarulhos 6
Hangzhou 6
Manchester 6
Norwalk 6
Recife 6
Atlanta 5
Bắc Ninh 5
Cape Town 5
Chicago 5
Dhaka 5
Formosa 5
Franca 5
Heidelberg 5
Hillsboro 5
Totale 4.750
Nome #
Risks of breast and ovarian cancer for women harboring pathogenic missense variants in BRCA1 and BRCA2 compared with those harboring protein truncating variants 133
Antitumour activity of trabectedin in myelodysplastic/myeloproliferative neoplasms 113
Breast and renal cancer-Derived endothelial colony forming cells share a common gene signature 108
34. Trabectedin and indole-3-carbinol combination in heavily pretreated metastatic breast cancer: Results of a pilot clinical study 95
ACUTE UPPER GASTROINTESTINAL BLEEDING (AUGB) IN ITALY: AN INTERIM ANALYSIS OF THE ORGANIZATIONAL ASPECTS CARING AN EVOLVING DISEASE 88
Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients 81
Ado-trastuzumab emtansine (T-DM1) in HER2+ advanced breast cancer patients: does pretreatment with pertuzumab matter? 79
Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues. 77
Precision medicine in Salivary Gland Carcinoma: Insights from breast and prostate cancer 77
Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study 76
27P * Common gene signature expressed by breast and kidney cancers-derived endothelial colony forming cells 76
Multinational characterization of neurological phenotypes in patients hospitalized with COVID-19 76
Analysis of SEMA6B gene expression in breast cancer: Identification of a new isoform 72
Cellular and molecular determinants of all‐ trans retinoic acid sensitivity in breast cancer: Luminal phenotype and α expression 71
Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen - A pilot study in patients with refractory malignancies 71
Adding pertuzumab to adjuvant therapy for high-risk HER2-positive early breast cancer in APHINITY: a GRADE analysis 71
Adipose-derived mesenchymal stem cells (ASCs) may favour breast cancer recurrence via HGF/c-Met signaling 71
In vitro Cytotoxic Effect of Trabectedin on JMML AND CMML Cell Populations 70
TRANSFUSION STRATEGY AND DEATH RISK IN PATIENTS WITH ACUTE NON-VARICEAL UPPER GASTRO INTESTINAL BLEEDING (NV-UGIB) IN ITALY: A PROSPECTIVE MULTICENTER OBSERVATIONAL STUDY 70
Alternative Splicing in Adhesion- and Motility-Related Genes in Breast Cancer 69
PREDICTIVE FACTORS OF MORTALITY IN ACUTE GASTROINTESTINAL BLEEDING IN ITALY (AUGIB): A NEW PRE-ENDOSCOPY PROGNOSTIC MODEL FROM A MULTICENTER STUDY 67
Allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in Europe 66
A Remote Monitoring System to Optimize the Home Management of Oral Anticancer Therapies (ONCO-TreC): Prospective Training-Validation Trial 66
Analysis of Italian BRCA1/2 Pathogenic Variants Identifies a Private Spectrum in the Population from the Bergamo Province in Northern Italy 65
Clinical Review on the Management of Breast Cancer Visceral Crisis 64
Bone-Active Drugs in Pre-Menopausal Women with Breast Cancer Under Hormone Deprivation Therapies 64
Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study 64
A Prognostic Model Based on Residual Cancer Burden and Tumor-Infiltrating Lymphocytes on Residual Disease after Neoadjuvant Therapy in HER2+ Breast Cancer 63
From cancer patients to cancer survivors: the issue of Cardioncology--a biological perspective. 63
A randomized multicenter study of optimal circadian time of vinorelbine combined with chronomodulated 5-fluorouracil in pretreated metastatic breast cancer patients: EORTC trial 05971 63
Prospective multicenter quality assessment of endotherapy of biliary stones: does center volume matter? 63
Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: the OnCovid Inflammatory Score 62
An ICT infrastructure to integrate clinical and molecular data in oncology research 62
trattamento conservativo dell' osteonecrosi spontaea del ginocchio in fase iniziale con campi pulsati: studio a 2 anni di follow-up minimo 61
A male patient with acromegaly and breast cancer: treating acromegaly to control tumor progression 61
Monitoring changing patterns in HER2 addiction by liquid biopsy in advanced breast cancer patients 60
OUTPATIENT MANAGEMENT OF PATIENTS WITH GLASGOW-BLATCHFORD BLEEDING SCORE LOW-RISK UPPER-GASTROINTESTINAL HEMORRHAGE: A MULTICENTER VALIDATION STUDY IN ITALY 60
Absence of the K303R estrogen receptor alpha mutation in breast cancer patients exhibiting different responses to aromatase inhibitor anastrozole neoadjuvant treatment 60
SAFETY PROFILE AND TOLERABILITY OF 'TRABECTEDIN AND INDOLE-3-CARBINOL COMBINATION IN REFRACTORY ADVANCED BREAST CANCER. PRELIMINARY RESULTS OF PHASE 1 CLINICAL STUDY 60
Opportunities and Challenges of Synthetic Data Generation in Oncology 59
Real-World Effectiveness of Denosumab and Bisphosphonates on Risk of Vertebral Fractures in Women with Breast Cancer Undergoing Treatment with Aromatase Inhibitors 59
Clinical toxicity of cryopreserved circulating progenitor cells infusion 58
Specialist palliative and end-of-life care for patients with cancer and SARS-CoV-2 infection: a European perspective 58
Poor outcome of patients with resectable breast cancer receiving adjuvant high-dose sequential chemotherapy following preoperative treatment 57
Circulating CD33+large mononuclear cells contain three distinct populations with phenotype of putative antigen-presenting cells including myeloid dendritic cells and CD14+monocytes with their CD16+subset 57
Remodelling of the Ca2+ signalling machinery in endothelial progenitor cells isolated from breast cancer patients 57
ONCO-i2b2: Improve Patients Selection through Case-Based Information Retrieval TechniquesData Integration in the Life Sciences 57
Correction: Everolimus (Eve) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: New lessons for clinical practice from the EVA study (Oncotarget (2018) 9:77 (34639-34640) DOI: 10.18632/oncotarget.25874) 56
Time-Dependent COVID-19 Mortality in Patients With Cancer: An Updated Analysis of the OnCovid Registry 56
Incidence of human cytomegalovirus infection in patients with refractory solid tumors receiving nonmyeloablative allogeneic stem cell transplants versus recipients of standard SCT for hematologic malignancies 56
Evaluation of infectious complications and immune recovery following high-dose chemotherapy (HDC) and autologous peripheral blood progenitor cell transplantation (PBPC-T) in 148 breast cancer patients 56
Relationship between size and thiazole orange fluorescence of platelets in patients undergoing high-dose chemotherapy 56
A Network-Based Data Integration Approach to Support Drug Repurposing and Multi-Target Therapies in Triple Negative Breast Cancer 56
Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2−) advanced breast cancer patients: New insights beyond clinical trials. The EVA study 56
From seaside to bedside: Current evidence and future perspectives in the treatment of breast cancer using marine compounds 55
Phase II study with ifosfamide, carboplatin, etoposide (ICE regimen) at intermediate dosage for advanced non small cell lung cancer (NSCLC) 55
Cellular and molecular determinants of breast cancer sensitivity to all-trans retinoic acid: Identification of a gene expression fingerprint predicting responsiveness 55
Trabectedin for the treatment of breast cancer 54
Heterogeneity of triple-negative breast cancer: understanding the Daedalian labyrinth and how it could reveal new drug targets 53
Denosumab improves trabecular bone score in relationship with decrease in fracture risk of women exposed to aromatase inhibitors 53
Common Misconceptions about Diet and Breast Cancer: An Unclear Issue to Dispel 53
MORTALITY IN UPPER GASTROINTESTINAL BLEEDING IN ITALY: DATA FROM NATIONAL SURVEY 53
Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: influence of dose and stem cell source shows better outcome with rich marrow 53
Epithelial tumour cell detection and the unsolved problems of nested RT-PCR: A new sensitive one step method without false positive results 53
Cytotoxic chemotherapy preceding apheresis of peripheral blood progenitor cells can affect the early reconstitution phase of naive T cells after autologous transplantation 53
AurkA controls self-renewal of breast cancer-initiating cells promoting wnt3a stabilization through suppression of miR-128 53
No correlation between plasma D-dimer levels and lymph node involvement in operable breast cancer 53
Short commentaries on data published by Petit et al. on locoregional risk after lipofilling in breast cancer patients 53
An epirubicin/paclitaxel combination mobilizes large amounts of hematopoietic progenitor cells in patients with metastatic breast cancer showing optimal response to the same chemotherapy regimen 52
T-DM1 and brain metastases: Clinical outcome in HER2-positive metastatic breast cancer 52
Commentary: Improvement in diagnostic-therapeutic care pathways for women with migraine: an Italian Delphi panel 52
STEM-CELL FACTOR AND INTERLEUKIN-6, ALONE OR IN COMBINATION WITH GRANULOCYTE-COLONY-STIMULATING FACTOR, DO NOT AFFECT THE GROWTH OF SOLID TUMOR-CELL LINES 51
T-cell dynamics after high-dose chemotherapy in adults: elucidation of the elusive CD8(+) subset reveals multiple homeostatic T-cell compartments with distinct implications for immune competence 51
The Role of Female Reproductive Hormones in the Association between Migraine and Breast Cancer: An Unanswered Question 50
Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies 50
Profiling cancer gene mutations in longitudinal epithelial ovarian cancer biopsies by targeted next-generation sequencing: a retrospective study 50
Prolyl-isomerase Pin1 controls normal and cancer stem cells of the breast 50
Long-term survival in a fraction of patients with metastatic breast cancer who received consolidation therapy with high-dose chemotherapy and autologous stem cell transplant between 2000 and 2015: an EBMT registry-based study 50
Targeting triple negative breast cancer: Is p53 the answer? 50
Resistance to platinum-based chemotherapy is associated with epithelial to mesenchymal transition in epithelial ovarian cancer 50
Targeting the EWS-FLI1 transcription factor in Ewing sarcoma 50
Erlotinib administration for advanced non-small cell lung cancer during the first 2 months of unrecognized pregnancy 49
Pulmonary function and complications following chemotherapy and stem cell support in breast cancer 49
Clinical and pathological factors predicting long-term disease control with lapatinib and capecitabine for patients with HER2 positive metastastic breast cancer: results from a multicenter retrospective study 49
COVID-19 Sequelae and the Host Pro-Inflammatory Response: An Analysis From the OnCovid Registry 48
Determinants of enhanced vulnerability to coronavirus disease 2019 in UK patients with cancer: a European study 48
Hodgkin's disease as unusual presentation of post-transplant lymphoproliferative disorder after autologous hematopoietic cell transplantation for malignant glioma 48
Four-day infusion of fluorouracil plus vinorelbine as salvage treatment of heavily pretreated metastatic breast cancer 48
Patient similarity by joint matrix trifactorization to identify subgroups in acute myeloid leukemia 48
Retinoids and breast cancer: from basic studies to the clinic and back again 48
Charting the Course in Sequencing Antibody-Drug Conjugates in Breast Cancer 47
Gene expression profiling and prediction of response to hormonal neoadjuvant treatment with anastrozole in surgically resectable breast cancer 47
Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2 47
Inclusion of Platinum Agents in Neoadjuvant Chemotherapy Regimens for Triple-Negative Breast Cancer Patients: Development of GRADE (Grades of Recommendation, Assessment, Development and Evaluation) Recommendation by the Italian Association of Medical Oncology (AIOM) 47
Two Missense Variants Detected in Breast Cancer Probands Preventing BRCA2-PALB2 Protein Interaction 47
Trastuzumab-Related Cardiotoxicity in Early Breast Cancer: A Cohort Study 47
Regulation of aromatase expression in breast cancer treated with anastrozole neoadjuvant therapy 47
Incidence and relevance of QTc-interval prolongation caused by tyrosine kinase inhibitors 47
COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry 47
Editorial: Trabectedin, lurbinectedin, and other marine-derived anticancer alkaloids on solid cancer: Mechanisms of action, clinical impact, and future perspectives 46
Totale 6.003
Categoria #
all - tutte 64.172
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 64.172


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202132 0 0 0 0 0 0 0 0 0 17 3 12
2021/2022474 4 1 4 17 5 6 7 12 183 80 136 19
2022/20231.057 248 48 135 86 98 62 5 53 100 140 67 15
2023/20241.012 71 80 157 47 36 197 54 46 27 31 100 166
2024/20251.583 43 7 12 20 23 273 104 85 218 418 172 208
2025/20264.305 655 290 374 740 243 154 1.011 242 327 269 0 0
Totale 8.567